EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims against The Medicines Company – MDCO

NEW YORK--(BUSINESS WIRE)--

The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of The Medicines Company MDCO resulting from allegations that The Medicines Company may have issued materially misleading business information to the investing public.

On April 9, 2015, The Medicines Company announced that it expects net revenue in the range of $125 million to $130 million for the first quarter of 2015, which reflects a 29% to 26% decrease from the first quarter of 2014 due to lowering sales of Angiomax. The Company expects net revenue from sales of Angiomax to be in the range of $97 million to $105 million compared to $155.7 million in the first quarter of 2014. The Chairman and CEO of The Medicines Company, Clive Meanwell, remarked that the declining sales of Angiomax "reflects our customers' current uncertainty regarding the product's patent exclusivity in the United States past June 2015" and that "[w]e appreciate our customers' concerns about managing their pharmaceutical inventories." On this news, shares of The Medicines Company fell sharply during after-hours trading on April 9, 2015.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by The Medicines Company investors. If you purchased shares of The Medicines Company on or before April 9, 2015, please visit the website at http://rosenlegal.com/cases-572.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.